Over the past 12 months, 7 insiders at Artiva Biotherapeutics, Inc. filed 24 open-market SEC Form 4 transactions on ARTV: 15 purchases worth $104.7M and 9 sales worth $741K. Insiders have been net buyers over this period. The most recent filing was on Jul 24, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 24, 26 | Ra Capital Management, L.p.Director, 10% Owner | BUY | 41.3K | $9.99 | $413K |
| Jul 13, 26 | Ra Capital Management, L.p.Director, 10% Owner | BUY | 6.6K | $8.94 | $59K |
| Jul 10, 26 | Ra Capital Management, L.p.Director, 10% Owner | BUY | 15.1K | $8.97 | $135K |
| Jun 26, 26 | Ra Capital Management, L.p. | BUY | 1.9K | $8.98 | $17K |
| Jun 25, 26 | Ra Capital Management, L.p. | BUY | 31.0K | $8.88 | $275K |
| Jun 16, 26 | Ra Capital Management, L.p. | BUY | 124.9K | $8.89 | $1.1M |
| Jun 15, 26 | Ra Capital Management, L.p. | BUY | 15.4K | $8.99 | $139K |
| Jun 12, 26 | Ra Capital Management, L.p. | BUY | 391.0K | $8.57 | $3.4M |
| Jun 11, 26 | Ra Capital Management, L.p. | BUY | 548.6K | $7.91 | $4.3M |
| Jun 10, 26 | Ra Capital Management, L.p. | BUY | 103 | $7.00 | $721 |
| Jun 9, 26 | Ra Capital Management, L.p. | BUY | 479.0K | $6.91 | $3.3M |
| May 19, 26 | Fred AslanChief Executive Officer | SELL | 27.1K | $9.01 | $244K |
| May 19, 26 | Subhashis BanerjeeChief Medical Officer | SELL | 7.0K | $9.01 | $63K |
| May 19, 26 | Jennifer BushCOO, CLO, Compliance Officer | SELL | 8.8K | $9.01 | $79K |
| May 19, 26 | Christopher HoranChief Tech Operations Officer | SELL | 7.0K | $9.01 | $63K |
| May 19, 26 | Heather RaymonSVP, Research and Development | SELL | 3.1K | $9.01 | $28K |
| May 11, 26 | Gc Corp. | BUY | 1.09M | $11.52 | $12.5M |
| May 11, 26 | Ra Capital Management, L.p. | BUY | 6.51M | $11.52 | $75.0M |
| Dec 15, 25 | Fred AslanPresident and CEO | SELL | 3.2K | $6.00 | $19K |
| Nov 17, 25 | Fred AslanPresident and CEO | SELL | 6.4K | $3.38 | $22K |
| Oct 17, 25 | Fred AslanPresident and CEO | SELL | 25.5K | $6.00 | $153K |
| Aug 15, 25 | Fred AslanPresident and CEO | SELL | 25.5K | $2.73 | $70K |
| Jul 22, 24 | 5am Partners Vi, LlcTenPercentOwner | BUY | 833.3K | $12.00 | $10.0M |
| Jul 22, 24 | Gc Cell CorpTenPercentOwner | BUY | 1.67M | $12.00 | $20.0M |
| Jul 22, 24 | Yong-jun HuhDirector | BUY | 1.67M | $12.00 | $20.0M |
| Jul 22, 24 | Peter KolchinskyDirector,TenPercentOwner | BUY | 7.65M | $12.00 | $91.7M |
| Jul 22, 24 | Venbio Global Strategic Gp Iii, LtdTenPercentOwner | BUY | 416.7K | $12.00 | $5.0M |
Over the past 12 months, insiders at Artiva Biotherapeutics, Inc. filed 15 open-market purchases worth $104.7M and 9 sales worth $741K on ARTV, which makes them net buyers over the period. The most recent Form 4 was filed on Jul 24, 26.
The largest recent open-market ARTV insider purchase in our data was $91.7M by Peter Kolchinsky, Director,TenPercentOwner, filed on Jul 22, 24.
7 different insiders at Artiva Biotherapeutics, Inc. filed open-market SEC Form 4 transactions on ARTV over the last 12 months.
InsiderTape plots every ARTV insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Artiva Biotherapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →